Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/patient-reported-outcomes-pros-as-part-of-value-based-care-can-shape-CL0t2GJd3y
References (33)
-
(Loftus P, Winslow R. FDA approves Bristol-Myers’s Yervoy, Opdivo for treatment of melanoma. The Wall Street Journal. October 1, 2015.)
Loftus P, Winslow R. FDA approves Bristol-Myers’s Yervoy, Opdivo for treatment of melanoma. The Wall Street Journal. October 1, 2015.Loftus P, Winslow R. FDA approves Bristol-Myers’s Yervoy, Opdivo for treatment of melanoma. The Wall Street Journal. October 1, 2015., Loftus P, Winslow R. FDA approves Bristol-Myers’s Yervoy, Opdivo for treatment of melanoma. The Wall Street Journal. October 1, 2015.
-
(2010)
Patient-reported outcomes labeling for products approved by the office of hematology and oncology products of the US Food and Drug Administration -
(Nivolumab (Opdivo) FDA approval-US Food and Drug Administration; October 9, 2015. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm466576.htm.)
Nivolumab (Opdivo) FDA approval-US Food and Drug Administration; October 9, 2015. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm466576.htm.Nivolumab (Opdivo) FDA approval-US Food and Drug Administration; October 9, 2015. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm466576.htm., Nivolumab (Opdivo) FDA approval-US Food and Drug Administration; October 9, 2015. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm466576.htm.
-
Lisa Raedler (2015)
Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma.American health & drug benefits, 8 Spec Feature
-
Keytruda) FDA approval-US Food and Drug Administration -
(Matter-Walstra K, Schwenkglenks M, Aebi S, et al. A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous NSCLC including PD-L1 testing. J Thoracic Oncol. 2016. http://www.jto.org/article/S1556-0864(16)30507-X/abstract.)
Matter-Walstra K, Schwenkglenks M, Aebi S, et al. A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous NSCLC including PD-L1 testing. J Thoracic Oncol. 2016. http://www.jto.org/article/S1556-0864(16)30507-X/abstract.Matter-Walstra K, Schwenkglenks M, Aebi S, et al. A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous NSCLC including PD-L1 testing. J Thoracic Oncol. 2016. http://www.jto.org/article/S1556-0864(16)30507-X/abstract., Matter-Walstra K, Schwenkglenks M, Aebi S, et al. A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous NSCLC including PD-L1 testing. J Thoracic Oncol. 2016. http://www.jto.org/article/S1556-0864(16)30507-X/abstract.
-
Nivolumab for previously treated locally advanced or metastatic squamous non-small cell lung cancer -
(Centers for Medicare and Medicaid Services Value-Based Programs. CMS.Gov. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Value-Based-Programs/Value-Based-Programs.html.)
Centers for Medicare and Medicaid Services Value-Based Programs. CMS.Gov. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Value-Based-Programs/Value-Based-Programs.html.Centers for Medicare and Medicaid Services Value-Based Programs. CMS.Gov. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Value-Based-Programs/Value-Based-Programs.html., Centers for Medicare and Medicaid Services Value-Based Programs. CMS.Gov. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Value-Based-Programs/Value-Based-Programs.html.
-
L. Diaz, A. Bardelli (2014)
Liquid biopsies: genotyping circulating tumor DNA.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 6
-
(Pembrolizumab (Keytruda) FDA approval-US Food and Drug Administration; October 2, 2015. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm465650.htm.)
Pembrolizumab (Keytruda) FDA approval-US Food and Drug Administration; October 2, 2015. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm465650.htm.Pembrolizumab (Keytruda) FDA approval-US Food and Drug Administration; October 2, 2015. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm465650.htm., Pembrolizumab (Keytruda) FDA approval-US Food and Drug Administration; October 2, 2015. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm465650.htm.
-
E. Garon, N. Rizvi, R. Hui, N. Leighl, A. Balmanoukian, J. Eder, A. Patnaik, C. Aggarwal, M. Gubens, L. Horn, E. Carcereny, M. Ahn, E. Felip, Jong-Seok Lee, M. Hellmann, O. Hamid, J. Goldman, J. Soria, M. Dolled-Filhart, R. Rutledge, Jin Zhang, J. Lunceford, Reshma Rangwala, G. Lubiniecki, C. Roach, K. Emancipator, L. Gandhi (2015)
Pembrolizumab for the treatment of non-small-cell lung cancer.The New England journal of medicine, 372 21
-
K. Matter-Walstra, M. Schwenkglenks, S. Aebi, K. Dedes, J. Diebold, Mario Pietrini, D. Klingbiel, R. Moos, O. Gautschi (2016)
A Cost‐Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD‐L1 TestingJournal of Thoracic Oncology, 11
-
E. Heitzer, Peter Ulz, J. Geigl (2015)
Circulating tumor DNA as a liquid biopsy for cancer.Clinical chemistry, 61 1
-
(Hematology/Oncology (Cancer) Approvals and Safety Notifications. US Food and Drug Administration. http://www.fda.gov.)
Hematology/Oncology (Cancer) Approvals and Safety Notifications. US Food and Drug Administration. http://www.fda.gov.Hematology/Oncology (Cancer) Approvals and Safety Notifications. US Food and Drug Administration. http://www.fda.gov., Hematology/Oncology (Cancer) Approvals and Safety Notifications. US Food and Drug Administration. http://www.fda.gov.
-
A. Gnanasakthy, C. Demuro, M. Clark, E. Haydysch, E. Ma, V. Bonthapally (2016)
Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 16
-
T. Seto, K. Kiura, M. Nishio, K. Nakagawa, M. Maemondo, A. Inoue, T. Hida, N. Yamamoto, H. Yoshioka, M. Harada, Y. Ohe, N. Nogami, K. Takeuchi, T. Shimada, Tomohiro Tanaka, T. Tamura (2013)
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.The Lancet. Oncology, 14 7
-
C. Cleeland, T. Mendoza, X. Wang, C. Chou, M. Harle, M. Morrissey, Martha Engstrom (2000)
Assessing symptom distress in cancer patientsCancer, 89
-
Medicare/Quality-Initiatives-Patient-Asse ssment-Instruments/Value-Based-Programs/Value-Based-Programs -
C. Cleeland, T. Mendoza, X. Wang, C. Chou, M. Harle, Marilynn Morrissey, Martha Engstrom (2000)
Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory.Cancer, 89 7
-
(Basch E, Wu A, Moinpour CM, et al. Steps for assuring rigor and adequate patient representation when using patient-reported outcome performance measures (PRO-PMs). Plymouth Meeting, PA, National Quality Measures Clearinghouse, 2013, pp 1–5.)
Basch E, Wu A, Moinpour CM, et al. Steps for assuring rigor and adequate patient representation when using patient-reported outcome performance measures (PRO-PMs). Plymouth Meeting, PA, National Quality Measures Clearinghouse, 2013, pp 1–5.Basch E, Wu A, Moinpour CM, et al. Steps for assuring rigor and adequate patient representation when using patient-reported outcome performance measures (PRO-PMs). Plymouth Meeting, PA, National Quality Measures Clearinghouse, 2013, pp 1–5., Basch E, Wu A, Moinpour CM, et al. Steps for assuring rigor and adequate patient representation when using patient-reported outcome performance measures (PRO-PMs). Plymouth Meeting, PA, National Quality Measures Clearinghouse, 2013, pp 1–5.
-
(2013)
Steps for assuring rigor and adequate patient representation when using patient-reported outcome performance measures (PRO-PMs) -
Opdivo) FDA approval-US Food and Drug Administration -
Q. Shi, X. Wang, T. Mendoza, K. Pandya, C. Cleeland (2009)
Assessing persistent cancer pain: a comparison of current pain ratings and pain recalled from the past week.Journal of pain and symptom management, 37 2
-
(Zill O, Mortimer S, Banks K, et al. Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. ASCO 2016. J Clin Oncol 2016;34:suppl; abstr LBA11501.)
Zill O, Mortimer S, Banks K, et al. Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. ASCO 2016. J Clin Oncol 2016;34:suppl; abstr LBA11501.Zill O, Mortimer S, Banks K, et al. Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. ASCO 2016. J Clin Oncol 2016;34:suppl; abstr LBA11501., Zill O, Mortimer S, Banks K, et al. Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. ASCO 2016. J Clin Oncol 2016;34:suppl; abstr LBA11501.
-
D. Cella, E. Hahn, S. Jensen, Z. Butt, C. Nowinski, N. Rothrock, K. Lohr (2015)
Patient-Reported Outcomes in Performance Measurement -
(National Institute for Health and Care Excellence. Nivolumab for previously treated locally advanced or metastatic squamous non-small cell lung cancer. https://s3.amazonaws.com/assets.fiercemarkets.net/public/005-LifeSciences/niceopdivoappraisal.pdf. Accessed Feb 29 2016.)
National Institute for Health and Care Excellence. Nivolumab for previously treated locally advanced or metastatic squamous non-small cell lung cancer. https://s3.amazonaws.com/assets.fiercemarkets.net/public/005-LifeSciences/niceopdivoappraisal.pdf. Accessed Feb 29 2016.National Institute for Health and Care Excellence. Nivolumab for previously treated locally advanced or metastatic squamous non-small cell lung cancer. https://s3.amazonaws.com/assets.fiercemarkets.net/public/005-LifeSciences/niceopdivoappraisal.pdf. Accessed Feb 29 2016., National Institute for Health and Care Excellence. Nivolumab for previously treated locally advanced or metastatic squamous non-small cell lung cancer. https://s3.amazonaws.com/assets.fiercemarkets.net/public/005-LifeSciences/niceopdivoappraisal.pdf. Accessed Feb 29 2016.
-
(2015)
FDA approves Bristol-Myers’s Yervoy, Opdivo for treatment of melanoma -
H. Borghaei, L. Paz-Ares, L. Horn, D. Spigel, M. Steins, N. Ready, L. Chow, E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhäufl, O. Arrieta, M. Burgio, J. Fayette, H. Léna, E. Poddubskaya, D. Gerber, S. Gettinger, C. Rudin, N. Rizvi, L. Crinò, G. Blumenschein, S. Antonia, C. Dorange, C. Harbison, F. Finckenstein, J. Brahmer (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.The New England journal of medicine, 373 17
-
Oliver Zill, S. Mortimer, K. Banks, R. Nagy, Darya Chudova, C. Jackson, A. Baca, Joseph Ye, R. Lanman, Amirali Talasaz, H. Eltoukhy, R. Kurzrock (2016)
Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA.Journal of Clinical Oncology, 34
-
J. Brahmer, K. Reckamp, P. Baas, L. Crinò, W. Eberhardt, E. Poddubskaya, S. Antonia, A. Płużański, E. Vokes, E. Holgado, D. Waterhouse, N. Ready, J. Gainor, O. Frontera, L. Havel, M. Steins, M. Garassino, J. Aerts, M. Dómine, L. Paz-Ares, M. Reck, C. Baudelet, C. Harbison, B. Lestini, D. Spigel (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.The New England journal of medicine, 373 2
-
E. Basch, C. Snyder, K. McNiff, Rebecca Brown, Suzanne Maddux, M. Smith, T. Atkinson, D. Howell, A. Chiang, W. Wood, N. Levitan, A. Wu, M. Krzyzanowska (2014)
Patient-reported outcome performance measures in oncology.Journal of oncology practice, 10 3
-
(National Quality Forum: patient-reported outcomes in performance measurement. Washington, DC, National Quality Forum, January 10, 2013. http://www.qualityforum.org/Projects/n-r/Patient-Reported_Outcomes/Patient-Reported_Outcomes.aspx.)
National Quality Forum: patient-reported outcomes in performance measurement. Washington, DC, National Quality Forum, January 10, 2013. http://www.qualityforum.org/Projects/n-r/Patient-Reported_Outcomes/Patient-Reported_Outcomes.aspx.National Quality Forum: patient-reported outcomes in performance measurement. Washington, DC, National Quality Forum, January 10, 2013. http://www.qualityforum.org/Projects/n-r/Patient-Reported_Outcomes/Patient-Reported_Outcomes.aspx., National Quality Forum: patient-reported outcomes in performance measurement. Washington, DC, National Quality Forum, January 10, 2013. http://www.qualityforum.org/Projects/n-r/Patient-Reported_Outcomes/Patient-Reported_Outcomes.aspx.
-
R. Goeree, J. Villeneuve, J. Goeree, J. Penrod, L. Orsini, A. Monfared (2016)
Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomesJournal of Medical Economics, 19
- Publisher
- Springer Journals
- Copyright
- Copyright © 2017 by The Author(s)
- Subject
- Medicine & Public Health; Internal Medicine
- ISSN
- 2366-1070
- eISSN
- 2366-1089
- DOI
- 10.1007/s40487-016-0038-7
- Publisher site
- See Article on Publisher Site
Abstract
Patient reported outcomes (PROs) are commonly integrated into clinical trials for new cancer therapies or treatment modalities; however, beyond a cursory review during the registration process for a new drug, these important measures of patient satisfaction and cost-effectiveness are often under-used in daily practice. We cite literature under-scoring the value of PROs not only in clinical trials, but in practical decision making and how such metrics can help guide the oncologist and the patient in choosing the best and most cost-effective therapy for their cancer. This is especially critical with the advent of new immunotherapies that are proving to be therapeutically beneficial for many patients, but not all, and at substantial cost in terms of toxicities and financial impact.
Journal
Oncology and Therapy – Springer Journals
Published: Jan 5, 2017